2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE ... outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so ...

Eli Lilly (LLY ... over the past month versus the Zacks S&P 500 composite's -3.5% change. The Zacks Large Cap Pharmaceuticals industry, to which Lilly belongs, has lost 5.6% over this period.

Eli Lilly (LLY ... compared to the Zacks S&P 500 composite's -2.8% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Lilly falls in, has lost 5.7%.

Some of the larger M&A deals of 2024 were Eli Lilly’s buyout of Morphic ... In contrast, the Zacks S&P 500 composite has risen 26.2%. Based on the forward 12-month price-to-earnings (P/E ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Is the stock market settling down after days of interest-rate-fueled selling hitting the Nasdaq Composite? Shortly after the ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks kept indexes in check. The S&P 500 edged up 0.1% Tuesday, and three out of ...